Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial

Publication

Newly Diagnosed Multiple Myeloma

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial

German-speaking myeloma multicenter group (GMMG)

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

PMID: 32034285

Leukemia; 2020 Jul

EudraCT No. 2010-019173-16

Details

GMMG - The German Speaking Myeloma Multicenter Group

---

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

J Hematol Oncol;2019

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Leukemia; 2021 March